KemPharm, Inc (KMPH)

Etorro trading 970x250
KemPharm, Inc (KMPH) Logo

About KemPharm, Inc

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm’s lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Address: 1180 Celebration Boulevard, Celebration, FL, United States, 34747

KemPharm, Inc News and around…

Latest news about KemPharm, Inc (KMPH) common stock and company :

KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
17 May, 2022 Yahoo! Finance

KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.

KemPharm Acquires Battered Orphazyme's Arimoclomol Program For $13M
16 May, 2022 FinancialContent

KemPharm Inc(NASDAQ: KMPH) hasagreed to acquireOrphazyme A/S's(in reconstruction) (OTC: ORPHY) ...

KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
16 May, 2022 Yahoo! Finance

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S. Food and Drug Administration (FDA) as early as the First Quarter of 2023 Conference call and live audio webcast with slide presentation is scheduled for tomorrow, May 16, 2022, at 8:30 a.m., EDT CELEBRATION, Fla

VTWV's Holdings Could Mean 35% Gain Potential
13 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $167.60 per unit.

Recap: KemPharm Q1 Earnings
12 May, 2022 FinancialContent

KemPharm (NASDAQ:KMPH) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about ...

KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
12 May, 2022 Yahoo! Finance

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, May 12, 2022, at 5:00 p.m. ET Filed Investigational New Drug (IND) application with U.S. Food and Drug Administration (FDA) for KP1077, a serdexmethylphenidate (SDX)-based product candidate for idiopathic hypersomnia (IH) Initiation of a Phase 2 trial (KP1077.D01) expected in the second half of 2022, with a second trial in patients with narcolepsy expected to begin the quarter following start of KP1077.D01 Dosed

Earnings Preview For KemPharm
11 May, 2022 FinancialContent

KemPharm (NASDAQ:KMPH) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know ...

KemPharm to Present at Multiple Upcoming Investor Conferences
11 May, 2022 Yahoo! Finance

CELEBRATION, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that members of management will participate in three upcoming in-person investor conferences. Details regarding KemPharm’s presentations are as follows: Event: RBC Capital Markets Global Healthcare Conference (Fireside Chat)Date

KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)
05 May, 2022 Yahoo! Finance

Upon IND clearance, KemPharm anticipates initiating KP1077 Phase 2 IH trial as early as the second half of 2022 CELEBRATION, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced the submission of an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Ad

KemPharm to Report First Quarter 2022 Financial Results
04 May, 2022 Yahoo! Finance

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET CELEBRATION, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that the Company will host a conference call and live audio webcast on Thursday, May 12, 2022, at 5:00 p.m. ET, to discuss its corporate and

The Technology Helping Existing FDA-Approved Drugs Target More Effectively
03 May, 2022 FinancialContent

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing ...

Benzinga Announces This Week's All Access Guests
28 Apr, 2022 FinancialContent

Benzinga is thrilled to announce the guest lineup for our next All Access show, sponsored by TiiCKER, set to air Friday, April 29 at ...

26 Stocks Moving in Monday's Pre-Market Session
25 Apr, 2022 FinancialContent

Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares rose 88.4% to $2.30 in pre-market trading. Erytech Pharma recently announced ...

Notable Friday Option Activity: CLX, KMPH, JNJ
22 Apr, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Clorox Co (CLX), where a total volume of 5,773 contracts has been traded thus far today, a contract volume which is representative of approximately 577,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 49% of CLX's average daily trading volume over the past month, of 1.2 million shares..

KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study
20 Apr, 2022 Yahoo! Finance

KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.

KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
19 Apr, 2022 Yahoo! Finance

Cardiovascular safety is a key component of the KP1077 product profile; Topline data comparing SDX to other stimulant treatments expected in Q3 2022 CELEBRATION, Fla., April 19, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that the first subject has been dosed in a Phase 1 clinical trial designed to

Notable Friday Option Activity: BZH, UPST, KMPH
01 Apr, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Beazer Homes USA, Inc. (BZH), where a total of 1,941 contracts have traded so far, representing approximately 194,100 underlying shares..

Stocks That Hit 52-Week Lows On Thursday
31 Mar, 2022 FinancialContent

On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The ...

KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
30 Mar, 2022 Yahoo! Finance

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing and commercializing therapeutics targeting rare central nervous system (CNS) and neurodegenerative conditions;Advancing development of KP1077, a serdexmethylphenidate (SDX) based product candidate for idiopathic hypersomnia (IH), as KemPharm’s lead candidate: Pre-Investigational New Drug (IND) process with the

Earnings Scheduled For March 30, 2022
30 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth ...

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
27 Mar, 2022 FinancialContent

Biotech stocks reversed course in the week endingMarch 25, as an increase in risk appetite prompted traders to move money out of ...

KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference
24 Mar, 2022 Yahoo! Finance

CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at Maxim’s 2022 Virtual Growth Conference being held March 28-30, 2022. Registered investors will be able to view the pre-recorded presentation by Dr. Mickle highlighting KemPharm’s business and rece

Noteworthy Wednesday Option Activity: KMPH, WDAY, OLLI
23 Mar, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in KemPharm Inc (KMPH), where a total of 5,640 contracts have traded so far, representing approximately 564,000 underlying shares. That amounts to about 143.3% of KMPH's average daily trading volume over the past month of 393,705 shares..

First Week of November 18th Options Trading For KemPharm (KMPH)
21 Mar, 2022 FinancialContent

Investors in KemPharm Inc (KMPH) saw new options become available this week, for the November 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

KemPharm's SDX Higher Dose Shows Potential Against Sleep Disorders
21 Mar, 2022 FinancialContent

KemPharm Inc(NASDAQ: KMPH)completed its analysisof the full data set from its Phase 1 clinical trial of ...

KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
21 Mar, 2022 Yahoo! Finance

Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep disorders Upcoming anticipated development milestones for KP1077 include: IND filing as early as Q2 2022; Phase 2 trial initiation in IH patients and announce results of study to examine safety related to cardiovascular effects expected in 2H 2022 CELEBRATION, Fla., March 21, 2022 (GLOBE NEWSWIRE)

KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
16 Mar, 2022 Yahoo! Finance

KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement CELEBRATION, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company has earned a $1.975 million fee from Corium, Inc., (Corium), a portfolio company of Gurnet Point Capital, following the approval of

Notable Tuesday Option Activity: BX, KMPH, EXPE
15 Mar, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Blackstone Inc (BX), where a total of 18,720 contracts have traded so far, representing approximately 1.9 million underlying shares. That amounts to about 41.2% of BX's average daily trading volume over the past month of 4.5 million shares..

KemPharm to Report Fourth Quarter and Full-Year 2021 Results
10 Mar, 2022 Yahoo! Finance

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022, 5:00 p.m. ET CELEBRATION, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, March 30, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the fourth qu

KemPharm is Now Oversold (KMPH)
04 Mar, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

KemPharm, Inc (KMPH) is a NASDAQ Common Stock listed in , ,

970x250